Corvus Pharmaceuticals (CRVS) Study update summary

Study overview and design

• Phase 1 randomized, placebo-controlled, blinded, dose exploration study of soquelitinib in moderate-to-severe atopic dermatitis, enrolling 72 adults who failed prior topical or systemic therapy, across four cohorts with 4–8 weeks of treatment and up to 90 days of follow-up.

• Patients were randomized to different dosing regimens, with cohort 4 receiving the highest dose and longest treatment (eight weeks).

• Patient demographics and baseline disease severity were well balanced between active and placebo groups.

• No concomitant topical steroids allowed; prior systemic therapy permitted; 14 U.S. sites participated.

• Primary endpoint was safety; secondary endpoints included EASI percent change, EASI75, EASI90, and IGA 0/1 rates.

Efficacy results

• Rapid, dose-dependent clinical responses observed, with EASI75 rates up to 75%, EASI90 up to 25%, and IGA 0/1 up to 33% at highest dose, outperforming placebo.

• Mean EASI reduction reached up to 72% at 8 weeks (200 mg BID).

• Durable responses maintained 30–90 days after treatment discontinuation, with no rebound or need for rescue medication.

• Efficacy observed in patients with prior systemic therapy, including those resistant to other treatments.

Safety profile

• No severe or serious adverse events reported; adverse events were mild (grade 1–2), balanced between groups, and did not require dose modification or discontinuation.

• No clinically significant lab abnormalities, hematologic issues, or infection signals; no cases of conjunctivitis.

• Most common adverse events included transient headaches and mild gastrointestinal symptoms.